What is cd 20 and how does it impact how I should think about treatment for follicular lymphoma

According to the Leukemia & Lymphoma Society (LLS), CD20 is a protein found on the surface of most B-cell lymphomas, including follicular lymphoma. Think of it as a kind of "marker" or "flag" on lymphoma cells that helps your medical team identify and target these cancer cells.

The National Comprehensive Cancer Network (NCCN) Guidelines emphasize that CD20 is particularly important because it's the target for several effective treatments, particularly:

• Rituximab (Rituxan®)
• Obinutuzumab (Gazyva®)
• Other similar medications called "anti-CD20 antibodies"

According to ASCO (American Society of Clinical Oncology) Guidelines, testing for CD20 is a standard part of the initial lymphoma diagnosis process because:

1. It helps confirm the specific type of lymphoma
2. It helps determine if CD20-targeted therapies would be effective
3. It influences treatment planning and options

Important considerations:

• Most follicular lymphomas are CD20-positive, which is generally favorable because it means these targeted treatments can be used
• Your doctor will test your lymphoma cells for CD20 as part of your initial diagnosis
• The presence of CD20 often influences which treatment combinations might work best for you

Always consult with your healthcare team about your specific CD20 status and how it impacts your individual treatment options. They can explain how your CD20 status specifically affects your treatment plan.

Would you like me to explain more about any specific CD20-targeted treatments or testing procedures?